NASDAQ:INNT

Innovate Biopharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$1.11
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.11
Now: $1.11▼
$1.18
50-Day Range
$0.56
MA: $0.97▼
$1.42
52-Week Range
$0.37
Now: $1.11▼
$1.67
Volume3.41 million shs
Average Volume525,982 shs
Market Capitalization$45.87 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.39
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Innovate Biopharmaceuticals logo

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INNT
Previous Symbol
CUSIPN/A
CIK1551986
Webwww.innovatebiopharma.com
Phone919-275-1933
Employees8
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio0.35
Quick Ratio0.35

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.27) per share
Price / Book-4.11

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-27,050,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-234.42%

Miscellaneous

Outstanding Shares41,325,000
Market Cap$45.87 million
Next Earnings DateN/A
OptionableOptionable

Headlines

BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases
April 13, 2021 |  finance.yahoo.com
Kintara Taking The Lead In Developing New And Innovative Rare Cancer Therapies
April 5, 2021 |  markets.businessinsider.com
Casi Pharmaceuticals Inc (CASI) Chairman and CEO Wei-wu He Bought $6.2 million of Shares
March 30, 2021 |  finance.yahoo.com
Reflect Scientific Inc. Ends 2020 with Significant Increase in Revenues and Profits; Files Form 10 for Registration of Securities
March 30, 2021 |  markets.businessinsider.com
Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides 2021 Business Update
March 29, 2021 |  finanznachrichten.de
AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline
March 26, 2021 |  markets.businessinsider.com
CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock
March 24, 2021 |  finance.yahoo.com
Pomerantz Law Firm Announces the Filing of a Class Action against Athenex, Inc., and Certain Officers - ATNX
March 24, 2021 |  benzinga.com
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
March 23, 2021 |  finance.yahoo.com
Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update
March 22, 2021 |  ca.finance.yahoo.com
North America’s largest end-to-end biopharmaceutical manufacturing facility coming to N.C., creating 725 jobs
March 18, 2021 |  msn.com
Dare Bioscience Inc. (NASDAQ: DARE) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
March 17, 2021 |  marketwatch.com
AsclepiX Therapeutics, Inc. Appoints Robert J. Dempsey as Chief Executive Officer and President
March 17, 2021 |  benzinga.com
XORTX Therapeutics Inc.: XORTX to Present at "Zoom With LD MICRO"
March 16, 2021 |  finanznachrichten.de
Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q4 2020 Results - Earnings Call Transcript
March 11, 2021 |  seekingalpha.com
Marinus Pharmaceuticals Inc (MRNS) Former VP, CFO & Treasurer Edward F Smith Sold $718,337 ...
March 11, 2021 |  finance.yahoo.com
North America $81 Billion Life Science Tools Market to 2027: Growth of Cell & Gene Therapies & Increasing Demand for Biopharmaceuticals
March 10, 2021 |  markets.businessinsider.com
Innovation Pharma’s COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most Effective Against SARS-CoV-2
March 10, 2021 |  finance.yahoo.com
LabCorp makes Fast Company's 'Most Innovative Companies' list
March 9, 2021 |  bizjournals.com
Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates
March 8, 2021 |  finanznachrichten.de
See More Headlines

MarketRank™

Overall MarketRank™

0.48 out of 5 stars

Medical Sector

1609th out of 2,019 stocks

Pharmaceutical Preparations Industry

674th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

What stocks does MarketBeat like better than Innovate Biopharmaceuticals?

Wall Street analysts have given Innovate Biopharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Innovate Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its quarterly earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.11).
View Innovate Biopharmaceuticals' earnings history.

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the following people:
  • Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
  • Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
  • Dr. Christopher P. Prior, Consultant (Age 66)
  • Jerry Gardner M.D., Head of Clinical Strategy
  • Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)

Who are some of Innovate Biopharmaceuticals' key competitors?

Some companies that are related to Innovate Biopharmaceuticals include Eton Pharmaceuticals (ETON), Genprex (GNPX), scPharmaceuticals (SCPH), Tiziana Life Sciences (TLSA), Lantern Pharma (LTRN), Harrow Health (HROW), AVEO Pharmaceuticals (AVEO), DiaMedica Therapeutics (DMAC), Enlivex Therapeutics (ENLV), OncoSec Medical (ONCS), Zynerba Pharmaceuticals (ZYNE), Assembly Biosciences (ASMB), Heat Biologics (HTBX), Exicure (XCUR) and Satsuma Pharmaceuticals (STSA).
View all of INNT's competitors.

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), (CGC), Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Micron Technology (MU), Nabriva Therapeutics (NBRV), Neurotrope (NTRP) and Aurora Cannabis (ACB).

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $1.11.

How much money does Innovate Biopharmaceuticals make?

Innovate Biopharmaceuticals has a market capitalization of $45.87 million.

How many employees does Innovate Biopharmaceuticals have?

Innovate Biopharmaceuticals employs 8 workers across the globe.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is www.innovatebiopharma.com.

Where are Innovate Biopharmaceuticals' headquarters?

Innovate Biopharmaceuticals is headquartered at 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]


This page was last updated on 4/14/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.